Gastroenterologists underestimate Crohn’s disease and UC in patients

27 October 2014
abbvie-logo-big

Most physicians underestimate the severity of moderate or severe inflammatory bowel disease, specifically Crohn’s disease (CD) or ulcerative colitis (UC), according to the results of a survey from US drugmaker AbbVie (NYSE: ABBV) of 200 gastroenterologists using clinical indices to evaluate a patient’s disease severity.

The survey, which assessed physicians’ use of the Harvey-Bradshaw Index and the total Mayo Score indices that physicians use to evaluate the intensity of CD and UC, respectively, showed that in the case study of severe UC, 81% of the physicians underestimated the disease severity, while 19% correctly assessed the severity of the disease.

In the severe CD case study, 76% of the physicians underestimated the disease severity and 25% correctly assessed the severity of the disease. In the case study of moderate UC, 67% of the physicians underestimated disease severity, and 32% correctly assessed the severity of the disease. In the moderate CD case study, 55% of the physicians underestimated disease severity and 44% correctly assessed the severity of the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical